Skip to content

MDMA research published in 2013

Page 2 of 3: studies 21 to 40 of 41, newest first. Back to the MDMA overview

Studies

Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus

Life Science July 24, 2013 M. Angoa-Perez, Michael J. Kane, Nieves Herrera-Mundo et al. 41 citations

Aims Mephedrone is a stimulant drug of abuse with close structural and mechanistic similarities to methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA). Although mephedrone does not damage dopamine nerve endings it increases the neurotoxicity of amphetamine, methamphetamine and MDMA. The effects of mephedrone on serotonin (5HT) nerve endings are not fully understood, with some...

Neurotoxicity of Methamphetamine and 3,4-methylenedioxymethamphetamine

Life Science July 24, 2013 Laura E. Halpin, Stuart A. Collins, Bryan K. Yamamoto 195 citations

Amphetamines are a class of psychostimulant drugs that are widely abused for their stimulant, euphoric, empathogenic and hallucinogenic properties. Many of these effects result from acute increases in dopamine and serotonin neurotransmission. Subsequent to these acute effects, methamphetamine and 3,4 methylenedioxymethamphetamine (MDMA) produce persistent damage to dopamine and serotonin nerve...

α1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans

Journal of Clinical Psychopharmacology July 13, 2013 Cédric M. Hysek, Anja E. Fink, Linda D. Simmler et al. 57 citations

Preclinical studies implicate a role for α₁-noradrenergic receptors in the effects of psychostimulants, including 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). The present study evaluated the effects of the α₁-noradrenergic receptor antagonist doxazosin on the acute pharmacodynamic and pharmacokinetic response to MDMA in 16 healthy subjects. Doxazosin (8 mg/d) or placebo was administered...

Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research

Human Psychopharmacology: Clinical and Experimental July 1, 2013 A. C. Parrott 184 citations

AIMS: This paper aimed to review how scientific knowledge about the human psychobiology of MDMA has developed over time. METHODS: In this paper, the empirical findings from earlier and later studies will be reviewed. RESULTS: When MDMA was a 'novel psychoactive substance', it was not seen as a drug of abuse, as it displayed loss of efficacy. However, recreational users display a unique pattern...

DOI: 10.1002/hup.2318 (opens in new tab) MDMA Ecstasy Behavioral neuroscience Clinical psychology

Age differences in (±) 3,4‐methylenedioxymethamphetamine (MDMA)‐induced conditioned taste aversions and monoaminergic levels

Developmental Psychobiology June 15, 2013 Jennifer L. Cobuzzi, Kayla Siletti, Zachary E. Hurwitz et al. 15 citations

Preclinical work indicates that adolescent rats appear more sensitive to the rewarding effects and less sensitive to the aversive effects of abused drugs. The present investigation utilized the conditioned taste aversion (CTA) design to measure the relative aversive effects of (±)3,4-methylenedioxymethamphetamine (MDMA; 0, 1.0, 1.8, or 3.2 mg/kg) in adolescent and adult Sprague-Dawley rats....

Acquisition of MDMA self‐administration: pharmacokinetic factors and MDMA‐induced serotonin release

Addiction Biology June 14, 2013 Sarah Bradbury, Judith Bird, Joyce Colussi‐mas et al. 59 citations

Abstract The current study aimed to elucidate the role of pharmacokinetic ( PK ) parameters and neurotransmitter efflux in explaining variability in (±) 3, 4‐methylenedioxymethamphetamine ( MDMA ) self‐administration in rats. PK profiles of MDMA and its major metabolites were determined after the administration of 1.0 mg/kg MDMA (iv) prior to, and following, the acquisition of MDMA...

Can MDMA Play a Role in the Treatment of Substance Abuse?

Current Drug Abuse Reviews June 1, 2013 Lisa Jerome, Shira Schuster, B. Yazar-Klosinski 36 citations

A wider array of treatments are needed for people with substance abuse disorders. Some psychedelic compounds have been assessed as potential substance abuse treatments with promising results. MDMA may also help treat substance abuse based on shared features with psychedelic compounds and recent reports indicating that MDMAassisted psychotherapy can reduce symptoms of PTSD. Narrative reports and...

Identification of novel psychoactive drug use in Sweden based on laboratory analysis – initial experiences from the STRIDA project

Scandinavian Journal of Clinical and Laboratory Investigation May 22, 2013 Anders Helander, Olof Beck, Robert Hägerkvist et al. 82 citations

AIM: The study aimed to collect information concerning the increasing use of new psychoactive substances, commonly sold through online shops as 'Internet drugs' or 'legal highs', or in terms of masked products such as 'bath salts' and 'plant food'. METHODS: The Karolinska Institutet and Karolinska University Laboratory and the Swedish Poisons Information Centre have initiated a project called...

DOI: 10.3109/00365513.2013.793817 (opens in new tab) MDMA Synthetic cannabinoids Mephedrone Designer drug +6

Single oral doses of (±) 3,4-methylenedioxymethamphetamine (‘Ecstasy’) produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations

The International Journal of Neuropsychopharmacology May 1, 2013 Melanie Mueller, Jie Yuan, Una D. Mccann et al.

Abstract: Repeated doses of the popular recreational drug methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) are known to produce neurotoxic effects on brain serotonin (5-HT) neurons but it is widely believed that typical single oral doses of MDMA are free of neurotoxic risk. Experimental and therapeutic trials with MDMA in humans are underway. The mechanisms by which MDMA produces neurotoxic...

Verbal Memory Deficits Are Correlated with Prefrontal Hypometabolism in 18FDG PET of Recreational MDMA Users

PLoS One April 9, 2013 Oliver G. Bosch, Michael Wagner, Frank Jessen et al. 34 citations

Verbal learning and recall deficits of recreational MDMA users are correlated with glucose hypometabolism in prefrontal and parietal cortex, while word recognition was additionally correlated with mediotemporal hypometabolism. We conclude that memory deficits of MDMA users arise from combined fronto-parieto-mediotemporal dysfunction.

DOI: 10.1371/journal.pone.0061234 (opens in new tab) MDMA Ecstasy Hippocampus Dorsolateral prefrontal cortex +2

Discriminative‐stimulus effects of 3,4‐methylenedioxy‐N‐methylamphetamine (MDMA) and a novel MDMA quatenary analog

The FASEB Journal April 1, 2013 Jonathan M. Slezak, Melanie Mueller, George A. Ricaurte et al.

MDMA (ecstasy), popularized as a “club drug,” is a psychoactive and abused substance. It is often assumed that the behavioral effects of MDMA are due to central actions, though this has not been tested. Using a quaternary analog of MDMA (qMDMA) we tested that assumption by training male Sprague‐Dawley rats (n = 6) to discriminate intraperitoneal (i.p.) injections of 1.7 mg/kg of MDMA HCl from...

5-Iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects.

Toxicology Letters March 27, 2013 Maurizio Coppola, Raffaella Mondola 20 citations

In 2010, an internet snapshot of EMCDDA anticipated the presence of 5-iodo-2-aminoindan (5-IAI) within the recreational drug market. In 2011, this compound, a psychoactive derivative of 2-aminoindane, was identified in recreational products sold in the United Kingdom. 5-IAI is a rigid analogue of p-iodoamphetamine producing MDMA-like effects. The aim of this paper is to summarize the clinical,...

Memory impairment and hippocampus specific protein oxidation induced by ethanol intake and 3, 4‐Methylenedioxymethamphetamine (MDMA) in mice

Journal of Neurochemistry March 25, 2013 Clara Ros‐simó, Maria Moscoso‐castro, Jéssica Ruiz‐medina et al. 35 citations

Abstract Ethanol and 3, 4‐Methylenedioxymethamphetamine ( MDMA ) are popular recreational drugs widely abused by adolescents that may induce neurotoxic processes associated with behavioural alterations. Adolescent CD 1 mice were subjected to ethanol intake using the drinking in the dark ( DID ) procedure, acute MDMA or a combination. Considering that both drugs of abuse cause oxidative stress...

DOI: 10.1111/jnc.12247 (opens in new tab) MDMA Hippocampus Oxidative stress Radial arm maze +4

Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells.

Toxicology Letters February 4, 2013 Patrícia Silva Ferreira, Tiago Bernandes Nogueira, Vera Marisa Costa et al.

"Ecstasy" (3,4-methylenedioxymethamphetamine or MDMA) is a widely abused recreational drug, reported to produce neurotoxic effects, both in laboratory animals and in humans. MDMA metabolites can be major contributors for MDMA neurotoxicity. This work studied the neurotoxicity of MDMA and its catechol metabolites, α-methyldopamine (α-MeDA) and N-methyl-α-methyldopamine (N-Me-α-MeDA) in human...

Chiral separation of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers using batch chromatography with peak shaving recycling and its effects on oxidative stress status in rat liver.

Journal of Pharmaceutical and Biomedical Analysis January 25, 2013 Tiago C Lourenço, Graziela C Bósio, Neila M Cassiano et al.

This work reports the multimiligram separation of 3,4-methylenedioxy-methamphetamine (MDMA) enantiomers using batch chromatography with peak shaving recycling. The effect of both enantiomers compared to the racemic mixture was examined on the oxidative stress status of rat liver. The enantiomeric purification was performed using a based cyclodextrin chiral selector and methanol:ammonium acetate...

Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA

The International Journal of Neuropsychopharmacology January 11, 2013 Tori L. Schaefer, Curtis E. Grace, A Braun et al. 24 citations

Abstract We previously showed that developmental 3,4-methylenedioxymethamphetamine (MDMA) treatment induces long-term spatial and egocentric learning and memory deficits and serotonin (5-HT) reductions. During brain development, 5-HT is a neurotrophic factor influencing neurogenesis, synaptogenesis, migration, and target field organization. MDMA (10 mg/kg × 4/d at 2 h intervals) given on...

The role of norephinephrine in the pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")

edoc (University of Basel) 2013 Cédric M. Hysek

The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is a widely used recreational drug, which produces strong psychological effects such as increased empathy and sociability. MDMA inhibits the uptake of and releases serotonin, dopamine, and norepinephrine via an interaction with the respective monoamine transporter. While the role of serotonin in the human pharmacology...

Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors.

International journal of adolescent medicine and health 2013 Yuriy Dobry, Timothy Rice, Leo Sher

At present, there are scarce clinical and basic lab data concerning the risk of acute serotonin toxicity from selective serotonin reuptake inhibitors (SSRIs) and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) co-administration. The health care community can strongly benefit from efforts to address the high risks associated with serotonin syndrome from this specific drug combination. The aim...

Modulation of 3,4-methylenedioxymethamphetamine effects by endocannabinoid system.

Current Pharmaceutical Design 2013 Olga Valverde, Marta Rodríguez‐arias

The amphetamine derivative 3, 4 Methylenedioxymethanphetamine (MDMA) is a powerful central nervous system stimulant that displays numerous pharmacological effects, including neurotoxicity. MDMA, or ecstasy, acts by inducing the release of different neurotransmitters depending on the animal species and, in particular, it produces the release of serotonin and dopamine. MDMA induces rewarding and...

The varieties of ecstasy experience: a phenomenological ethnography.

Journal of Psychoactive Drugs 2013 Sean Leneghan 6 citations

Ecstasy (MDMA) has attracted widespread attention with its association as a "recreational substance" that is concentrated in club and rave settings. This paper outlines a phenomenologically grounded ethnographic study of the experiences of ecstasy users in the Sydney, Australia, area. I espouse phenomenology as a framework for describing and understanding these experiences. A number of excerpts...